GlassScriptPhysician profile
Brian Mausser
NPI 1396518429
$2,105.77
in general payments reported to CMS, 2019-2025
18 companies · $1,163 in 2025
The $1,163 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $942 · 2025: $1,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,105.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $511.37 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $332.44 | 2024-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $214.49 | 2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $156.64 | 2024-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $99.73 | 2024-2025 | Qelbree |
| Axsome Therapeutics, INC. | $93.68 | 2024-2025 | Auvelity |
| Corium, LLC | $81.85 | 2024-2025 | Azstarys, Azstarys |
| Alkermes, INC. | $80.21 | 2024-2025 | Lybalvi, Aristada |
| Noven Therapeutics, LLC | $74.99 | 2024-2025 | Xelstrym |
| Janssen Pharmaceuticals, INC | $72.10 | 2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $70.54 | 2025 | Austedo Xr, Uzedy |
| Abbvie INC. | $60.35 | 2024-2025 | |
| Tempus Ai, INC | $56.02 | 2024 | |
| Ironshore Pharmaceuticals INC. | $55.43 | 2024 | |
| Neos Therapeutics, LP | $40.22 | 2025 | Adzenys Xr-Odt |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $38.92 | 2025 | Zurzuvae |
| Takeda Pharmaceuticals U.S.A., INC. | $34.28 | 2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $32.51 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Mausser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.